Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Successful immunogene therapy using colon cancer cells (colon 26) transfected with plasmid vector containing mature interleukin-18 cDNA and the Ig kappa leader sequence
Autore:
Yoshimura, K; Hazama, S; Iizuka, N; Yoshino, S; Yamamoto, K; Muraguchi, M; Ohmoto, Y; Noma, T; Oka, M;
Indirizzi:
Yamaguchi Univ, Sch Med, Dept Surg 2, Ube, Yamaguchi 7558505, Japan Yamaguchi Univ Ube Yamaguchi Japan 7558505 Ube, Yamaguchi 7558505, Japan Yamaguchi Univ, Sch Med, Dept Bioregulatory Funct, Ube, Yamaguchi 7558505,Japan Yamaguchi Univ Ube Yamaguchi Japan 7558505 , Ube, Yamaguchi 7558505,Japan Yamaguchi Univ, Sch Med, Dept Biochem 2, Ube, Yamaguchi 7558505, Japan Yamaguchi Univ Ube Yamaguchi Japan 7558505 Ube, Yamaguchi 7558505, Japan Ohtsuka Cellular Technol Inst, Kawauchi, Tokushima 7710192, Japan Ohtsuka Cellular Technol Inst Kawauchi Tokushima Japan 7710192 192, Japan
Titolo Testata:
CANCER GENE THERAPY
fascicolo: 1, volume: 8, anno: 2001,
pagine: 9 - 16
SICI:
0929-1903(200101)8:1<9:SITUCC>2.0.ZU;2-R
Fonte:
ISI
Lingua:
ENG
Soggetto:
GAMMA-INDUCING FACTOR; METH-A SARCOMA; TUMOR-CELLS; CONVERTING-ENZYME; IN-VIVO; T-CELLS; CYTOKINE; IL-18; MICE; FIBROBLASTS;
Keywords:
IL-18; gene therapy; plasmid; immunotherapy;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
26
Recensione:
Indirizzi per estratti:
Indirizzo: Yoshimura, K Yamaguchi Univ, Sch Med, Dept Surg 2, 1-1-1 Minami Kogushi, Ube, Yamaguchi7558505, Japan Yamaguchi Univ 1-1-1 Minami Kogushi Ube Yamaguchi Japan 7558505
Citazione:
K. Yoshimura et al., "Successful immunogene therapy using colon cancer cells (colon 26) transfected with plasmid vector containing mature interleukin-18 cDNA and the Ig kappa leader sequence", CANC GENE T, 8(1), 2001, pp. 9-16

Abstract

IL-18 is a novel cytokine that induces interferon (IFN)-gamma secretion and plays an important role in antitumor immunity. In the present study, we constructed plasmid vectors encoding the murine mature IL-18 cDNA linked with the Ig kappa leader sequence and the pro-IL-18 cDNA to estimate the efficacy of the mature IL-18 vector and to evaluate IL-18-producing tumor cells as a tumor vaccine. Colon 26 cells were transfected with the abovementionedvectors or with vector alone (mock). Reverse transcription-polymerase chain reaction analysis showed increased expression of murine IL-18 cDNA in both mature IL-18 and pro-IL-18 transfectants in comparison to that in mock transfected cells. The ability of the culture supernatants of mature IL-18 transfectants to induce IFN-gamma secretion was extremely high (40-140 pg/10(6) cells) in comparison to that of pro IL-18 transfectants (4-18 pg/ 10(6) cells). When injected into syngeneic BALB/c mice, the growth of mature IL-18 transfectants, but not pro-IL-18 transfectants, was significantly less than that in mock transfected cells (P<.01, by ANOVA and analysis of covariance). In addition, injection of colon 26 or Meth -A cells into mice immunized with a mature IL-18 transfectant revealed acquired immunity. Depletion ofnatural killer cells did not affect the growth of transfectants. However, the growth inhibitory effects were partially abrogated following treatment with anti-CD4(+) and anti-CD8(+) antibodies. These data suggest that the rejection of mature IL-18/colon 26 cells was mediated through T-cell activation. Gene therapy using mature IL-18 transfectants containing a plasmid vector and the Ig<kappa> leader sequence may be a useful tumor vaccine.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 03/07/20 alle ore 01:40:26